SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, ...
Austin, Texas, United States, December 18th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical-technology company ...
Doctors may soon be able to diagnose an elusive form of heart disease within seconds by using an AI model developed at ...
Pre-screening is crucial for athletes to reduce the risk of sudden cardiac death (SCD). However, 12 lead ECG screening alone is insufficient to prevent SCD. Objective This study aims to determine the ...
HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) ...
Please provide your email address to receive an email when new articles are posted on . Long-term continuous ECG monitoring with human oversight outperformed an artificial intelligence-based mobile ...
Huxley Medical, Inc. announced the SANSA(R) home sleep apnea test has received regulatory clearance from the United States Food and Drug Administration (FDA) to be used as a diagnostic ECG monitor, ...
After receiving word late last month that the FDA would not be issuing a 510(k) clearance to its cable-free electrocardiogram ...
I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.
Unlike any single-lead or 6-lead consumer device, HeartBeam’s patented cable-free technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback